FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2015381888> ?p ?o ?g. }

• W2015381888 endingPage "339" @default.
• W2015381888 startingPage "339" @default.
• W2015381888 abstract "Profile of certolizumab and its potential in the treatment of psoriatic arthritis Maria Sole Chimenti,1 Rosita Saraceno,2 Andrea Chiricozzi,2,3 Alessandro Giunta,2 Sergio Chimenti,2 Roberto Perricone11Unit of Rheumatology, Allergology, and Clinical Immunology, 2Unitof Dermatology, University of Rome Tor Vergata, Rome, Italy; 3Laboratory for Investigative Dermatology, Rockefeller University, New York,NY, USAAbstract: Psoriatic arthritis (PsA) is a chronic inflammatory arthropathy associated with psoriasis (PsO). PsA could be considered an enthesal disease because of the link between mechanical stress (entheses) and immunologically active tissue (synovium). Evidence of efficacy of anti-tumor necrosis factor alpha (TNF-α) is supported by reduction of histological vascularity and immune cell infiltrates in synovial tissue after treatment. Certolizumab pegol (CZP) is a polyethylene glycolylated (PEGylated) Fab′ fragment of a humanized monoclonal antibody that binds and neutralizes human TNF-α. The PEG moiety of the Fab fragment, markedly increases the half-life of CZP and confers to the drug a unique structure that differs from the other anti-TNF-α agents tested for the treatment of Crohn’s disease, rheumatoid arthritis, ankylosing spondylitis, axial spondyloarthritis, nonradiographic spondyloarthritis, PsO, and PsA. In contrast to other anti-TNF-α agents, CZP did not mediate increased levels of apoptosis, suggesting that these mechanisms are not essential for the anti-TNF-α efficacy in Crohn’s disease. As CZP, infliximab, and adalimumab, but not etanercept, almost completely inhibited lipopolysaccharide-induced interleukin-1 beta release from monocytes, this cytokine-production inhibition may be relevant for drug efficacy. Due to these characteristics, it has been demonstrated in clinical studies that CZP effectively improves signs and symptoms of arthritis and physical function and skin manifestations of PsO, with a safety profile similar to rheumatoid arthritis. This drug can be considered as a valid treatment in patients affected by PsA. The efficacy and tolerability profiles suggest CZP as a suitable antipsoriatic drug in the treatment of PsA.Keywords: psoriatic arthritis, certolizumab pegol, biological therapies, anti-TNF" @default.
• W2015381888 created "2016-06-24" @default.
• W2015381888 creator A5017062027 @default.
• W2015381888 creator A5053063613 @default.
• W2015381888 creator A5055412996 @default.
• W2015381888 creator A5055989807 @default.
• W2015381888 creator A5065367798 @default.
• W2015381888 creator A5075368922 @default.
• W2015381888 date "2013-04-01" @default.
• W2015381888 modified "2023-09-25" @default.
• W2015381888 title "Profile of certolizumab and its potential in the treatment of psoriatic arthritis" @default.
• W2015381888 cites W1527717973 @default.
• W2015381888 cites W1572018981 @default.
• W2015381888 cites W178778499 @default.
• W2015381888 cites W1964785646 @default.
• W2015381888 cites W1965918908 @default.
• W2015381888 cites W1979107859 @default.
• W2015381888 cites W1979232932 @default.
• W2015381888 cites W1979732206 @default.
• W2015381888 cites W1979938581 @default.
• W2015381888 cites W1990521474 @default.
• W2015381888 cites W1997106678 @default.
• W2015381888 cites W2007128909 @default.
• W2015381888 cites W2007929726 @default.
• W2015381888 cites W2015368628 @default.
• W2015381888 cites W2016563979 @default.
• W2015381888 cites W2026757352 @default.
• W2015381888 cites W2032792840 @default.
• W2015381888 cites W2035082041 @default.
• W2015381888 cites W2035198078 @default.
• W2015381888 cites W2035681584 @default.
• W2015381888 cites W2038595075 @default.
• W2015381888 cites W2039036372 @default.
• W2015381888 cites W2043024980 @default.
• W2015381888 cites W2047000833 @default.
• W2015381888 cites W2065310718 @default.
• W2015381888 cites W2066015053 @default.
• W2015381888 cites W2071238576 @default.
• W2015381888 cites W2073177499 @default.
• W2015381888 cites W2080538203 @default.
• W2015381888 cites W2095947548 @default.
• W2015381888 cites W2098330694 @default.
• W2015381888 cites W2099199787 @default.
• W2015381888 cites W2100736304 @default.
• W2015381888 cites W2106686862 @default.
• W2015381888 cites W2106964599 @default.
• W2015381888 cites W2108375718 @default.
• W2015381888 cites W2111113980 @default.
• W2015381888 cites W2118596556 @default.
• W2015381888 cites W2119684753 @default.
• W2015381888 cites W2121019867 @default.
• W2015381888 cites W2121294435 @default.
• W2015381888 cites W2122980756 @default.
• W2015381888 cites W2130935672 @default.
• W2015381888 cites W2131513768 @default.
• W2015381888 cites W2132041924 @default.
• W2015381888 cites W2133782563 @default.
• W2015381888 cites W2150703501 @default.
• W2015381888 cites W2154515402 @default.
• W2015381888 cites W2162868329 @default.
• W2015381888 cites W2166035803 @default.
• W2015381888 cites W2167795826 @default.
• W2015381888 cites W2171122996 @default.
• W2015381888 cites W2318611526 @default.
• W2015381888 cites W2332039632 @default.
• W2015381888 cites W2335318213 @default.
• W2015381888 cites W3047750585 @default.
• W2015381888 cites W79463722 @default.
• W2015381888 cites W3047687164 @default.
• W2015381888 doi "https://doi.org/10.2147/dddt.s31658" @default.
• W2015381888 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3633576" @default.
• W2015381888 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23620660" @default.
• W2015381888 hasPublicationYear "2013" @default.
• W2015381888 type Work @default.
• W2015381888 sameAs 2015381888 @default.
• W2015381888 citedByCount "25" @default.
• W2015381888 countsByYear W20153818882014 @default.
• W2015381888 countsByYear W20153818882016 @default.
• W2015381888 countsByYear W20153818882017 @default.
• W2015381888 countsByYear W20153818882018 @default.
• W2015381888 countsByYear W20153818882019 @default.
• W2015381888 countsByYear W20153818882020 @default.
• W2015381888 countsByYear W20153818882021 @default.
• W2015381888 countsByYear W20153818882022 @default.
• W2015381888 crossrefType "journal-article" @default.
• W2015381888 hasAuthorship W2015381888A5017062027 @default.
• W2015381888 hasAuthorship W2015381888A5053063613 @default.
• W2015381888 hasAuthorship W2015381888A5055412996 @default.
• W2015381888 hasAuthorship W2015381888A5055989807 @default.
• W2015381888 hasAuthorship W2015381888A5065367798 @default.
• W2015381888 hasAuthorship W2015381888A5075368922 @default.
• W2015381888 hasBestOaLocation W20153818881 @default.
• W2015381888 hasConcept C17991360 @default.
• W2015381888 hasConcept C203014093 @default.
• W2015381888 hasConcept C2776215756 @default.
• W2015381888 hasConcept C2776260265 @default.
• W2015381888 hasConcept C2777011040 @default.
• W2015381888 hasConcept C2777077863 @default.

• next